Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
USD 0.28
(1.32%)
USD 0.28
(1.32%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.99 Million USD | -172.64% |
| 2022 | -4.31 Million USD | -28.33% |
| 2021 | -1.04 Million USD | -270.05% |
| 2020 | -711.15 Thousand USD | 0.0% |
| 2018 | -577.22 Thousand USD | -207.12% |
| 2017 | -183.97 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.38 Million USD | -11.31% |
| 2024 Q2 | -1.48 Million USD | -29.88% |
| 2023 Q2 | -1.44 Million USD | 11.4% |
| 2023 Q1 | -1.63 Million USD | -125.43% |
| 2023 Q4 | -1.28 Million USD | 18.76% |
| 2023 Q3 | -1.57 Million USD | -9.11% |
| 2023 FY | - USD | -172.64% |
| 2022 Q3 | -491.19 Thousand USD | -45.68% |
| 2022 Q2 | -337.17 Thousand USD | 45.82% |
| 2022 Q1 | -622.34 Thousand USD | 35.98% |
| 2022 FY | - USD | -28.33% |
| 2022 Q4 | -723.45 Thousand USD | -47.28% |
| 2021 Q1 | -157.17 Thousand USD | 0.0% |
| 2021 FY | - USD | -270.05% |
| 2021 Q4 | -972.16 Thousand USD | -328.38% |
| 2021 Q3 | -226.94 Thousand USD | 30.36% |
| 2021 Q2 | -325.88 Thousand USD | -107.34% |
| 2020 FY | - USD | 0.0% |
| 2018 FY | - USD | -207.12% |
| 2017 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 97.341% |
| Theratechnologies Inc. | -10.31 Million USD | 61.304% |
| Safety Shot Inc | -12.18 Million USD | 67.25% |
| Cosmos Health Inc. | -17.06 Million USD | 76.611% |
| Cronos Group Inc. | -72.14 Million USD | 94.469% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.569% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 88.94% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 111.076% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -24.123% |
| ProPhase Labs, Inc. | -14.82 Million USD | 73.085% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 11.809% |
| Dynavax Technologies Corporation | 9.66 Million USD | 141.285% |
| Radius Health, Inc. | 38.31 Million USD | 110.417% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -69.742% |
| Alvotech | -484.86 Million USD | 99.177% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -4.347% |
| Alpha Teknova, Inc. | -25.53 Million USD | 84.374% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 97.488% |
| SCYNEXIS, Inc. | 73.47 Million USD | 105.431% |
| Harrow Health, Inc. | 9.72 Million USD | 141.043% |
| Biofrontera Inc. | -18.45 Million USD | 78.374% |
| DURECT Corporation | -24.68 Million USD | 83.833% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 104.061% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 103.65% |
| OptiNose, Inc. | -15.55 Million USD | 74.342% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 115.193% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 437.618% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -461.391% |
| SIGA Technologies, Inc. | 84.15 Million USD | 104.742% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 591.459% |
| Shineco, Inc. | -26.55 Million USD | 84.972% |
| Phibro Animal Health Corporation | 84.6 Million USD | 104.717% |
| Procaps Group S.A. | 104.02 Million USD | 103.836% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 52.498% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -10.311% |
| Viatris Inc. | 3.51 Billion USD | 100.113% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -4.347% |
| Rockwell Medical, Inc. | -4.69 Million USD | 14.984% |
| Incannex Healthcare Limited | -18.5 Million USD | 78.434% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -294.333% |
| Tilray Brands, Inc. | -72.84 Million USD | 94.522% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 101.294% |
| PetIQ, Inc. | 81.48 Million USD | 104.897% |
| Silver Spike Investment Corp. | 7.34 Million USD | 154.368% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 100.959% |
| Journey Medical Corporation | 1.92 Million USD | 307.738% |
| Alimera Sciences, Inc. | 7.27 Million USD | 154.847% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 5.252% |
| Assertio Holdings, Inc. | -222.44 Million USD | 98.206% |
| Embecta Corp. | 245.4 Million USD | 101.626% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 80.077% |
| Procaps Group, S.A. | 104.02 Million USD | 103.836% |
| PainReform Ltd. | -9.56 Million USD | 58.296% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 97.324% |
| Hempacco Co., Inc. | -12.77 Million USD | 68.758% |
| Talphera, Inc. | -9.84 Million USD | 59.453% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 102.45% |
| Alvotech | -484.86 Million USD | 99.177% |
| Lantheus Holdings, Inc. | 491 Million USD | 100.813% |
| Kamada Ltd. | 21.53 Million USD | 118.532% |
| Indivior PLC | 66 Million USD | 106.046% |
| Currenc Group, Inc. | -1.9 Million USD | -109.971% |
| Evoke Pharma, Inc. | -7.29 Million USD | 45.276% |
| Flora Growth Corp. | -45.87 Million USD | 91.3% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 80.077% |
| Evolus, Inc. | -41.81 Million USD | 90.455% |
| HUTCHMED (China) Limited | 25.52 Million USD | 115.632% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 101.653% |
| Akanda Corp. | -27.73 Million USD | 85.612% |